Assessment of the reversibility of resistance in the absence of antibiotics and its relationship with the resistance gene's fitness cost: a genetic study with mcr-1

IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Lancet Microbe Pub Date : 2024-08-01 DOI:10.1016/S2666-5247(24)00052-1
{"title":"Assessment of the reversibility of resistance in the absence of antibiotics and its relationship with the resistance gene's fitness cost: a genetic study with mcr-1","authors":"","doi":"10.1016/S2666-5247(24)00052-1","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The intensive use of antibiotics has resulted in strong natural selection for the evolution of antimicrobial resistance (AMR), but whether, and under what circumstances, the removal of antibiotics would result in a rapid reduction in AMR has been insufficiently explored. We aimed to test the hypothesis that in the simple, yet common, case of AMR conferred by a single gene, removing antibiotics would quickly reduce the prevalence of resistance if the AMR gene imposes a high fitness cost and costless resistance is extremely rare among its proximal mutants.</p></div><div><h3>Methods</h3><p>In this genetic study, to test our hypothesis, we used the <em>mcr-1</em> gene in <em>Escherichia coli</em>, which confers resistance to the last-resort antibiotic colistin, as a model. A high-throughput reverse genetics approach was used to evaluate <em>mcr-1</em> variants for their fitness cost and resistance levels relative to a non-functional construct, by measuring relative growth rates in colistin-free media and at 2 μg/mL and 4 μg/mL colistin. We identified costless resistant <em>mcr-1</em> mutants, and examined their properties within the context of the sequential organisation of <em>mcr-1</em>’s functional domains as well as the evolutionary accessibility of these mutations. Finally, a simple population genetic model incorporating the measured fitness cost was constructed and tested against previously published real-world data of <em>mcr-1</em> prevalence in colonised inpatients in China since the 2017 colistin ban in fodder additives.</p></div><div><h3>Findings</h3><p>We estimated the relative growth rates of 14 742 <em>mcr-1 E coli</em> variants (including the wild type), 3449 of which were single-nucleotide mutants. <em>E coli</em> showed 73·8% less growth per 24 h when carrying wild-type <em>mcr-1</em> compared with the non-functional construct. 6252 (42·4%) of 14 741 <em>mcr-1</em> mutants showed colistin resistance accompanied by significant fitness costs, when grown under 4 μg/mL colistin selection. 43 (0·3%) <em>mcr-1</em> mutants exhibited costless resistance, most of which contained multiple mutations. Among the 3449 single mutants of <em>mcr-1</em>, 3433 (99·5%) had a fitness cost when grown in colistin-free media, with a mean relative growth of 0·305 (SD 0·193) compared with the non-functional variant. 3059 (88·7%) and 1833 (53·1%) of 3449 single mutants outgrew the non-functional <em>mcr-1</em> in the presence of 2 μg/mL and 4 μg/mL colistin, respectively. Single mutations that gave rise to costless mutants were rare in all three domains of <em>mcr-1</em> (transmembrane domain, flexible linker, and catalytic domain), but the linker domain was enriched with cost-reducing and resistance-enhancing mutations and depleted with cost-increasing mutations. The population genetics model based on the experimental data accurately predicts the rapid decline in <em>mcr-1</em> prevalence in real-world data.</p></div><div><h3>Interpretation</h3><p>Many identified costless resistant variants that consist of multiple mutations are unlikely to evolve easily in nature. These findings for colistin and <em>mcr-1</em> might be applicable to other cases in which AMR entails a substantial fitness cost that cannot be mitigated in proximal mutants.</p></div><div><h3>Funding</h3><p>National Natural Science Foundation of China, and National Key Research and Development Program of China.</p></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":null,"pages":null},"PeriodicalIF":20.9000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666524724000521/pdfft?md5=1262172eff4a612dbc1b5de78e66ff6d&pid=1-s2.0-S2666524724000521-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Microbe","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666524724000521","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The intensive use of antibiotics has resulted in strong natural selection for the evolution of antimicrobial resistance (AMR), but whether, and under what circumstances, the removal of antibiotics would result in a rapid reduction in AMR has been insufficiently explored. We aimed to test the hypothesis that in the simple, yet common, case of AMR conferred by a single gene, removing antibiotics would quickly reduce the prevalence of resistance if the AMR gene imposes a high fitness cost and costless resistance is extremely rare among its proximal mutants.

Methods

In this genetic study, to test our hypothesis, we used the mcr-1 gene in Escherichia coli, which confers resistance to the last-resort antibiotic colistin, as a model. A high-throughput reverse genetics approach was used to evaluate mcr-1 variants for their fitness cost and resistance levels relative to a non-functional construct, by measuring relative growth rates in colistin-free media and at 2 μg/mL and 4 μg/mL colistin. We identified costless resistant mcr-1 mutants, and examined their properties within the context of the sequential organisation of mcr-1’s functional domains as well as the evolutionary accessibility of these mutations. Finally, a simple population genetic model incorporating the measured fitness cost was constructed and tested against previously published real-world data of mcr-1 prevalence in colonised inpatients in China since the 2017 colistin ban in fodder additives.

Findings

We estimated the relative growth rates of 14 742 mcr-1 E coli variants (including the wild type), 3449 of which were single-nucleotide mutants. E coli showed 73·8% less growth per 24 h when carrying wild-type mcr-1 compared with the non-functional construct. 6252 (42·4%) of 14 741 mcr-1 mutants showed colistin resistance accompanied by significant fitness costs, when grown under 4 μg/mL colistin selection. 43 (0·3%) mcr-1 mutants exhibited costless resistance, most of which contained multiple mutations. Among the 3449 single mutants of mcr-1, 3433 (99·5%) had a fitness cost when grown in colistin-free media, with a mean relative growth of 0·305 (SD 0·193) compared with the non-functional variant. 3059 (88·7%) and 1833 (53·1%) of 3449 single mutants outgrew the non-functional mcr-1 in the presence of 2 μg/mL and 4 μg/mL colistin, respectively. Single mutations that gave rise to costless mutants were rare in all three domains of mcr-1 (transmembrane domain, flexible linker, and catalytic domain), but the linker domain was enriched with cost-reducing and resistance-enhancing mutations and depleted with cost-increasing mutations. The population genetics model based on the experimental data accurately predicts the rapid decline in mcr-1 prevalence in real-world data.

Interpretation

Many identified costless resistant variants that consist of multiple mutations are unlikely to evolve easily in nature. These findings for colistin and mcr-1 might be applicable to other cases in which AMR entails a substantial fitness cost that cannot be mitigated in proximal mutants.

Funding

National Natural Science Foundation of China, and National Key Research and Development Program of China.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评估抗药性在无抗生素情况下的可逆性及其与抗药性基因的适应成本之间的关系:一项关于 mcr-1 的遗传研究。
背景:抗生素的大量使用导致了抗菌素耐药性(AMR)进化的强烈自然选择,但对于去除抗生素是否会导致抗菌素耐药性的快速降低以及在何种情况下会导致抗菌素耐药性的快速降低还没有进行充分的探讨。我们的目的是检验这样一个假设:在单个基因赋予AMR这一简单而又常见的情况下,如果AMR基因带来了很高的适应性成本,而且无成本抗性在其近端突变体中极为罕见,那么移除抗生素将迅速降低抗药性的流行率:在这项基因研究中,为了验证我们的假设,我们以大肠杆菌中的 mcr-1 基因为模型,该基因赋予了大肠杆菌对最后一种抗生素可乐定的耐药性。我们采用了一种高通量反向遗传学方法,通过测量在无可乐定培养基中以及在 2 微克/毫升和 4 微克/毫升可乐定培养基中的相对生长率,评估了 mcr-1 变体相对于无功能构建体的适应性成本和抗性水平。我们确定了无成本抗性 mcr-1 突变体,并结合 mcr-1 功能域的序列组织以及这些突变的进化可及性研究了它们的特性。最后,我们构建了一个简单的种群遗传模型,其中包含了测得的适应性成本,并根据之前公布的自2017年饲料添加剂中禁用可乐定以来中国结肠住院病人中mcr-1流行率的实际数据进行了测试:我们估算了 14 742 个 mcr-1 大肠杆菌变体(包括野生型)的相对生长率,其中 3449 个为单核苷酸突变体。与无功能构建体相比,携带野生型 mcr-1 的大肠杆菌每 24 小时的生长速度降低了 73-8%。在 14 741 个 mcr-1 突变体中,有 6252 个(42-4%)在 4 μg/mL 秋水仙素选择条件下生长时表现出秋水仙素抗性,并伴有显著的健康代价。43个(0-3%)mcr-1突变体表现出无代价抗性,其中大部分包含多个突变。在 3449 个 mcr-1 单突变体中,有 3433 个(99-5%)在无可乐定培养基中生长时产生了健康成本,与无功能变体相比,平均相对生长量为 0-305(标度 0-193)。3449 个单一突变体中,分别有 3059 个(88-7%)和 1833 个(53-1%)在 2 μg/mL 和 4 μg/mL 秋水仙素存在下超越了无功能的 mcr-1。在mcr-1的所有三个结构域(跨膜结构域、柔性连接子结构域和催化结构域)中,产生无成本突变体的单突变都很罕见,但连接子结构域富含降低成本和增强抗性的突变,而增加成本的突变则很少见。基于实验数据的群体遗传学模型准确预测了真实世界数据中 mcr-1 流行率的快速下降:许多已发现的由多个突变组成的无成本耐药变体在自然界中不可能轻易进化。这些关于秋水仙素和mcr-1的发现可能适用于其他情况,即AMR需要大量的适应性成本,而这种成本在近端突变体中无法减轻:基金项目:国家自然科学基金、国家重点研发计划。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Lancet Microbe
Lancet Microbe Multiple-
CiteScore
27.20
自引率
0.80%
发文量
278
审稿时长
6 weeks
期刊介绍: The Lancet Microbe is a gold open access journal committed to publishing content relevant to clinical microbiologists worldwide, with a focus on studies that advance clinical understanding, challenge the status quo, and advocate change in health policy.
期刊最新文献
Effect of pneumococcal conjugate vaccination on pneumococcal carriage in hospitalised children aged 2-59 months in Mongolia: an active pneumonia surveillance programme. Blood transcriptomic analyses do not support SARS-CoV-2 persistence in patients with post-COVID-19 condition with chronic fatigue syndrome. Saliva as a reliable, non-invasive specimen for detecting and monitoring Mycobacterium leprae. Endocarditis associated with contamination of cardiovascular bioprostheses with Mycobacterium chelonae: a collaborative microbiological study. Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1